EGFR and head and neck squamous cell carcinoma: Therefore, use of the EGFR antibody, Cetuximab or small-molecule EGFR tyrosine kinase inhibitors, Gefitinib and Erlotinib, to target the receptor has been well studied.8–10 Although Cetuximab is an approved HNSCC therapy, the overall impact on survival is modest.11,12 Moreover, Cetuximab is currently extremely expensive, which creates a major hurdle towards widespread treatment.